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Although radical cystectomy is a standard treatment in muscle-invasive bladder cancer,
bladder preservation therapy including transurethral resection of bladder tumor, radiother-
apy, and concurrent chemotherapy has been widely adopted, recently. This retrospective
analysis was performed to evaluate the survival rates and prognostic factors related to treat-
ment outcomes following bladder-preserving therapy including radiotherapy (RT) in bladder
cancer with a curative intent.
Materials and methods
We conducted a multi-institutional retrospective study of 152 patients with stage II-IV blad-
der cancer treated with curative RT between 2000 and 2010. There were 72 patients in
stage II, 49 in stage III, and 31 in stage IV. Ninety-seven patients were treated with concur-
rent chemoradiotherapy and fifty-five with RT alone. Radiation was delivered to the pelvis
(median 63 Gy), mainly with cisplatin. The median follow-up time was 35.5 months.
Results
Sixty-nine patients (45.4%) showed a complete response to RT. The 5-year overall survival
(OS) rate was 45.8%, the 5-year cause-specific survival (CSS) rate was 48.9%, and the 5-
year disease-free survival (DFS) rate was 20.8%. Univariate analysis revealed significant
differences in the following factors according to the survival rates: patient age, initial hemo-
globin level, clinical T stage, clinical N stage, clinical stage group, tumor response to RT,
hydronephrosis, and concurrent chemotherapy. Multivariate analysis also revealed a
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significant difference in patient age (p = 0.003 in OS, p<0.017 in CSS) and tumor response
to RT (p = 0.002 in OS, p<0.001 in CSS). Concurrent chemotherapy was significantly differ-
ent in the DFS rates (p = 0.046).
Conclusions
The survival rates reported herein are comparable to those from other studies, and tumor
response and concurrent chemoradiotherapy were significant prognostic factors for better
survival rates. Further randomized studies are needed to elucidate the impact of RT in blad-
der cancer.
Introduction
Bladder cancer is the 2nd most frequent genitourinary tumor; the incidence rate is high world-
wide, and the number of bladder cancer cases continues to increase in South Korea [1,2]. At
the initial diagnosis, approximately 30% of bladder cancer cases exhibit muscle-invasive blad-
der cancer (MIBC) and, although the remaining cases are non-MIBC, 30% of patients with
non-MIBC progress to invasive tumor during follow-up despite undergoing transurethral
resection of bladder tumor (TURBT) [3].
Radical cystectomy (RC) with bilateral pelvic lymph node dissection (PLND) and urinary
diversion has been a standard curative treatment for MIBC. Recent reports have revealed an
approximately 50% 5-year local control rate and a 40–60% 5-year overall survival (OS) rate [4–
6]. Additional reduction of the risk of recurrence, and improvement of OS have also been
reported with the use of cisplatin-based chemotherapy [7]. However, RC-related morbidity
and mortality cannot be disregarded. Although these results may have been influenced by sev-
eral factors including patient age and medical co-morbidities, a recent study reported that the
risk of perioperative mortality ranges from 0.8% to 2.7% [8,9].
For patients who are not eligible for radical surgery due to medical co-morbidities, and
those who want to conserve their native bladder, definitive radiotherapy (RT) is an appropriate
therapeutic option. Recently, use of TURBT and RT with or without concurrent chemotherapy
has been adopted for bladder conservation, to improve patient quality of life without
compromising oncologic outcomes [10]. Following bladder-preserving therapy, patients are
expected to have survival outcomes that are comparable to previously reported RC results, as
well as a better quality of life due to intact bladder function [6,11,12].
The authors retrospectively collected and analyzed clinical data from seven institutions
affiliated with the Korean Radiation Oncology Group (KROG) and reviewed the current treat-
ment status, analyzed clinical outcomes, and evaluated prognostic factors related to treatment
outcomes following bladder-preserving therapy.
Materials and methods
We retrospectively analyzed 152 patients with biopsy-proven, American Joint Committee on
Cancer (AJCC, 7th edition) stage II-IV bladder cancer, treated with bladder-preserving therapy
from January 2000 to December 2010 at seven institutions participated in the KROG 14–16
study. This study was approved by the Institutional Review Board (IRB) of each university hos-
pital or cancer center; Keimyung University Dongsan Medical Center IRB, Samsung Medical
Center IRB, National Cancer Center IRB, Severance Hospital IRB, Soonchunhyang University
Hospital Seoul IRB, Gyeongsang National University Hospital IRB, Seoul National University
Hospital IRB, and the need for informed consent was waived.
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Patients underwent physical examinations, cystoscopy with biopsy, complete blood count
(CBC), liver function tests, urinalysis, chest radiography, and computed tomography (CT) or
pelvic magnetic resonance imaging before treatment. Patient performance status was evaluated
according to the guidelines of the Eastern Cooperative Oncology Group (ECOG). A CBC was
performed at least once weekly during RT. When the absolute neutrophil count was<1,000/
mm3 or the platelet count was < 50,000/mm3, treatment was interrupted or delayed until the
patient’s condition recovered. Red blood cell transfusion was given to patients with hemoglo-
bin levels less than 10.0 g/dL.
TURBT was performed to obtain an accurate diagnosis and for maximal tumor removal. If
needed, repeated TURBT was performed during the follow-up period in patients with sus-
pected recurrence. Most patients underwent TURBT under spinal anesthesia. Usually, external
beam RT was delivered using 6, 10, 15, or 20 mega-voltage photon beams with a four-field
box technique, for 5 days each week over 7 weeks. The median fraction size was 1.8 Gy (range:
1.8–2.5). Irradiated fields were defined according to common criteria in the most patients, but
they were sometimes changed due to each physician’s decision. For the initial pelvic fields, in
most patients, the superior border was at the middle of the sacroiliac joint or at the L5–S1
interspace, and the interior border was at or just below the bottom of the obturator foramen.
The inferior border was sometimes extended to the bottom of the ischial tuberosity, depending
on disease involvement, with the prostatic urethra or bladder neck. The lateral border was 1.5–
2.0 cm lateral to the true pelvis, to encompass the bladder and the pelvic lymph nodes. On the
lateral portal, the anterior border was placed in front of the bladder and the posterior border
was set with an at least 3-cm margin behind the posterior border bladder wall. The portals
were reduced for most patients after 45 Gy (1.8 Gy per fraction), and a follow-up CT study was
performed. Boost treatment included an initial gross tumor volume with a 2-cm margin.
Neoadjuvant chemotherapy adapted before TURBT and RT, and concurrent chemotherapy
with RT were administered by intravenous infusion. Cisplatin was mainly administered as a
concurrent chemotherapeutic agent, and 40 mg/m2 was given every week on the first day of
the chemotherapy cycle (D1, D8, D15, and D22) within 16 hours after RT. Another regimen
(cisplatin and paclitaxel) was also adapted, and 50 mg/m2 of paclitaxel (D1, D8, and D15) and
15 mg/m2 of cisplatin (D1–3, D8–10, D15–17) were combined.
After completion of treatment, all patients were evaluated by radiation oncologists and uro-
logic oncologists at 3-month intervals for 1 year and at least 6 months thereafter. Complete
response (CR) was defined as no evidence of a gross tumor upon follow-up cystoscopic exami-
nation and biopsy, pelvic CT or MRI at 3 months after completion of treatment. Partial
response (PR) was defined as T < 1 according to the Radiation Therapy Oncology Group.
Loco-regional failure was defined as any disease lesions within pelvic radiation fields that
developed 3 months later and thereafter. Distant metastasis was defined as any disease occur-
ring outside of the pelvic radiation fields.
The OS rate was calculated from the time between diagnosis and date of death due to cause
any death as caused from cancer. Cause-specific survival (CSS) was calculated from the time
between diagnosis and date of death related to bladder cancer. Disease-free survival (DFS) was
calculated from the end of primary treatment to the date of diagnosing loco-regional recur-
rence or distant metastasis in patients with CR after RT. Kaplan-Meier analysis was performed
to estimate the OS, CSS, and DFS rates, with the log-rank test used to assess prognostic signifi-
cance and the Cox proportional hazards model used for multivariate analysis. A chi-square
test was used to analyze the relationship between factors among the two groups. A p-value less
than 0.05 was considered statistically significant. Statistical analyses were performed using
SPSS software (ver. 21.0; IBM Corp., Armonk, NY, USA).
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Results
The pretreatment characteristics of the 152 patients are listed in S1 Table. Patient age ranged
from 37 to 94 years with a median age of 72 years. In total, 121 (79.6%) patients were male and
31 (20.4%) were female. Gross hematuria was the most common initial symptom in 125
patients (82.2%), and 13 patients (8.6%) suffered from dysuria. Patients had several underlying
diseases, such as angina pectoris or acute myocardial infarction (10 patients), cerebrovascular
disease (6 patients), hypertension (46 patients), and diabetes mellitus (33 patients). Forty-eight
patients (31.6%) had a history of cigarette smoking.
In total, 141 (92.8%) patients showed a good performance status (ECOG grade of 0 or 1).
With the exception of 10 cases, all patients underwent TURBT. Of the 142 patients who under-
went TURBT, 92 (64.7%) underwent TURBT once and the other 50 (35.3%) underwent
TURBT more than once. Complete TURBT was observed in 99 patients (65.1%). Urothelial
cell carcinoma was the dominant type upon pathological examination (96.7%). Approximately
80% of the patients had high-grade tumors. Half of all patients were in clinical stage T2, and
more than 80% were had a clinically negative lymph node status. The AJCC stage was II in 72
patients (47.4%), III in 49 patients (32.2%), and IV in 31 patients (20.4%). Ninety-seven
patients (63.8%) had a solitary tumor in the bladder, and forty-six (30.3%) had multiple
tumors. Hydronephrosis was reported in 40 patients (26.3%), and 111 patients (73.0%) had
normal kidneys. The initial hemoglobin level ranged from 6.8 to 16.5 g/dL, with a median level
of 12.1 g/dL.
Neoadjuvant chemotherapy prior to TURBT and RT was administered in 50 patients
(32.9%). Concurrent chemotherapy with RT was adopted in 97 patients (63.8%), and the che-
motherapeutic regimen mainly comprised cisplatin-based agents. The total radiation dose ran-
ged from 43.2 to 70.2 Gy (median 63 Gy, typically 1.8 Gy per fraction). The median dose
administered to the pelvic lymph nodal area was 45 Gy and that to the bladder tumor was 63
Gy. More details of treatment variables are summarized in the S2 Table.
Three months after completion of treatment, 69 patients (45.4%) showed CR and 46
(30.3%) showed PR (S3 Table). Disease had progressed in 15 patients (9.9%) and 14 (9.2%)
had a stable disease status. Of the 69 patients with CR, 38 patients (55.1%) were alive without
evidence of disease on last follow-up. Of the rest 31 patients with failure after CR, loco-regional
failure was reported in 25 patients. The most common site of loco-regional failure after com-
plete response was the bladder (24 patients), and pelvic nodal failure was in 1 patient only. For
entire cohort, distant failure was reported in 40 patients (26.3%). The sites of distant metastasis
were various, and included bone, lung, brain, and lymph nodes above the common iliac chain.
S4 Table also showed clinical outcomes according to T stage. Higher rates of lymph nodal
metastasis and presence of gross residual tumor after TURBT were related to advanced T
stage. Although there was no statistical significance in tumor response after RT, 5-year OS and
CSS were significantly better in lower T stage group.
The 5-year OS rate was 45.8% (Panel A of S1 Fig), the 5-year CSS rate was 48.9% (Panel B
of S1 Fig), and the 5-year DFS rate was 20.8% (Panel C of S1 Fig) in all patients. The 3-year OS
rate was 56.9%, the 5-year CSS rate was 59.1%, and the 5-year DFS rate was 25.6%. Univariate
analysis revealed significant differences in patient age, clinical N stage, clinical stage group,
and tumor response to RT (S2 Fig) according to the OS, CSS, and DFS rates. The initial hemo-
globin level, clinical T stage, and hydronephrosis status were statistically significant in the OS
and CSS rates, and concurrent chemotherapy with RT (S3 Fig) was also significant when ana-
lyzing the DFS rates (S5 Table). There was no statistical significance between neoadjuvant che-
motherapy and survival outcomes including OS, CSS, and DFS. Multivariate analysis revealed
a significant difference in patient age (OS: 95% confidence interval [CI], 0.32 to 0.80; hazard
Bladder-preserving therapy for muscle-invasive bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0209998 January 17, 2019 4 / 9
ratio [HR], 0.51; p = 0.003; CSS: 95% CI, 0.35 to 0.90; HR, 0.56; p<0.017) and tumor response
to RT (OS: 95% CI, 0.30 to 0.76; HR, 0.48; p = 0.002; CSS: 95% CI, 0.27 to 0.69; HR, 0.43;
p<0.001) according to the OS and CSS rates. Concurrent chemotherapy (95% CI, 0.44 to 0.99;
HR, 0.66; p = 0.046) was significantly different according to the DFS rate (S6 Table).
Discussion
Although RC remains the standard therapy for treatment of MIBC, several recent reports have
shown comparable clinical outcomes using bladder-preserving therapy [13]. The present work
was a nationwide, multi-institutional retrospective study. The authors analyzed clinical data to
estimate the survival rates for MIBC, and to identify several prognostic factors related to sur-
vival rates and failure patterns following bladder-preserving therapy in MIBC; however, there
were differences in treatment protocols, including use of fractionation schemes in RT, chemo-
therapeutic regimens, and cycles among institutions.
The tumor response rates after RT and survival rates reported herein may appear unsatis-
factory compared to previous reports. The overall CR rate following bladder-preserving
therapy, including tri-modality therapy, which in turn includes TURBT, concurrent chemo-
therapy, and RT, was approximately 73%, ranging from 54.7% to 93% [13]. However, more
than one-third of the patients analyzed herein were not administered concurrent chemother-
apy due to their severe medical co-morbidities; therefore, the comparison was not direct. Of
the 97 patients who received concurrent chemotherapy and RT, 48 patients (49.5%) showed
CR after tri-modality therapy, although the chemotherapeutic regimens varied. Among previ-
ous reports, the 5-year OS rate was approximately 50%, ranging from 36% to 74%, and the
5-year CSS rate ranged from 50% to 82% [14–18]. A recent report of long-term outcomes by
the Radiation Therapy Oncology Group (RTOG) showed a 5-year OS rate of 57% and a 5-year
CSS rate of 71% [12]. Regarding the characteristics of the patient in the RTOG study, approxi-
mately two-thirds of patients were less than 70 years old and 60.6% were in clinical stage T2.
Only 10.6% of the patients had hydronephrosis. Considering that several different clinical
parameters are associated with a favorable outcome, such as unifocal tumor, absence of hydro-
nephrosis, clinical stage T2, and smaller tumor size [19,20], the patient characteristics
described in the present study were less favorable: half of all the patients were in clinical stage
T3 or T4, 30.3% had multiple tumors, 80.2% had a high-grade tumor, and 26.3% with hydro-
nephrosis. In the report by US ha et al., they reported laparoscopic versus open radical cystect-
omy results in South Korea as a single institutional retrospective study [21]. Three-year OS
rates were 64.2% - 72.6% and 3-year CSS rates were 73.0% - 75.3%, but direct comparison to
our results seems to be difficult due to the differences in patient characteristics including T
stage, N stage, and patient’s medical conditions.
In contrast to RC, treatment failure in the bladder is a common concern in bladder-preserv-
ing therapy, particularly for MIBC in the preserved bladder [22]. In the present study, 24
patients (34.7%) with CR showed in-bladder recurrence. Among previous studies, in-bladder
recurrence rates ranged from 19% to 58%, and MIBC recurrence was approximately half as
prevalent as intra-vesical recurrence [20,23,24]. Rodel et al. [20] reported 5-year cumulative
bladder cancer recurrence and MIBC recurrence rates of 41% and 28%, respectively. Regard-
ing in-bladder recurrence sites, Tunio et al. [16] reported that 21% of patients with initial CR
after tri-modality therapy showed MIBC recurrence, of which 69% were within the original
MIBC site.
There are several methods for achieving better bladder control: radiation dose escalation is
one possible solution. Hafeez et al. [25] reported the feasibility of simultaneous integrated
boost to 70 Gy without MIBC recurrence, even with low rates of late toxicity. Murthy et al.
Bladder-preserving therapy for muscle-invasive bladder cancer
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[26] also reported the use of dose escalation during image-guided intensity-modulated RT in a
prospective study. However, it is required to define accurate tumor location for dose escala-
tion. Recently, with using image-guide techniques such as cone-beam CT, lipiodol injection
around the residual tumor or tumor bed was introduced [27,28]. The procedure consists of
intramuscular injection of lipiodol, and verification of lipiodol location on cone-beam CT dur-
ing daily RT. However, wide use of this technique would be premature due to a lack of suffi-
cient clinical data.
As mentioned, cisplatin-based concurrent chemotherapy and radiotherapy has been
adapted for MIBC patients who are unfit for surgery. Recently, advances in cancer treatment
also have emphasized the role of the immune system in tumor growth and progression, and
intra-tumoral CD8+ T cells have been reported to associated with prognosis in cancer patients
[29,30]. Two immune checkpoint inhibitors including Atezoliumab, Pembrolizumab were
approved by US Food and Drug Administration (FDA) and European Medicines Agency
(EMA) as first-line therapy for cisplatin-ineligible advanced urothelial cancer in 2017 [31]. For
both MIBC and non-MIBC, there are also many ongoing clinical trials evaluating immune
checkpoint inhibitors as a monotherapy and combination therapy, and together with the iden-
tification of biomarkers, it would be elucidating the antitumor activity and helpful to improve
the efficacy of the treatments.
To define appropriate irradiation field is another concern related to loco-regional failure in
RT. In BC2001 trial, although clinical lymph node negative patients were included and the
irradiated target was bladder, pelvic lymph node failures were reported in only 4.9% after con-
current chemoradiotherapy [14]. In the present study, pelvic lymph node failure was also seen
in 1.2% (1 patient) among the 85 patients after concurrent chemoradiotherapy without clinical
lymph node involvement. Indeed, a randomized study comparing bladder only irradiation (65
Gy) with pelvic lymph nodal irradiation (45 Gy to whole pelvis and 20 Gy bladder boost)
showed similar rates in pelvic nodal failure [16]. These results imply that RT fields including
bladder only could be feasible in selected patients and concurrent chemotherapy might also
have targeted microscopic lymph nodal disease.
Our results identified several prognostic factors related to survival outcome, including
patient age, tumor response to RT and concurrent chemotherapy. The combination of concur-
rent chemotherapy and RT has been reported to show better clinical outcomes, including OS
and DFS [14,32]. In the Bladder Cancer 2001 (BC2001) study, the authors demonstrated
improved loco-regional DFS (67% vs. 54%, p = 0.03) and a trend toward increased OS (48% vs.
35%, p = 0.16), although the chemotherapeutic regimen was a combination of 5-fluorouracil
and mitomycin C [14]. Currently, weekly cisplatin-based chemotherapy with RT is the most
common combination treatment for MIBC, and it has been also administered, even as a
neoadjuvant or adjuvant chemotherapy (eg, MVAC and gemcitabine/cisplatin) with the inten-
tion of eradicating distant micro-metastases that are not treated by RT [4].
In the present study, there are several limitations, and foremost the limitations were origi-
nated from retrospective design. Therefore, this study is limited by several biases including
patient selection, data acquisition. It should be also noticed that patient data was heterogenous
from seven distinct institutions, and the patients were treated by multiple urologists, radiation
oncologists, and medical oncologists. Although our nationwide study represents the outcomes
in South Korea, this may also limit generalize the results to other regions.
Conclusion
Clinical outcomes including tumor response and survival rates are comparable to those from
other studies, and tumor response and concurrent chemotherapy are significant prognostic
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factors for better survival rates. Bladder preserving therapy seems to be an effective treatment
accomplishing competent oncologic outcomes with retaining native bladder, however careful
regular follow-up after treatment is also necessary to prevent and detect subsequent bladder
recurrence. Further randomized studies are needed to elucidate the impact of RT in bladder
cancer.
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